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Abstract 
Rare tumors, when considered as a group,
represent  a  significant  burden  to  society  as
they may account for up to 25% of the mortal  -
ity by cancer in nations like the United States.
In contrast with the current scenario in highly
incident cancer types, little progress has been
achieved in the treatment of the most rare can-
cers. The reasons for this apparent stagnation
are mostly intrinsic to logistical difficulties in
performing large clinical trials in rare diseases
and will be addressed further in this article.
Because  both  cancer  incidence  and  clinical
research are booming in emerging nations, we
also aim to address the current and future role
of these countries in research and the drug
development process in rare tumor types. 
Discussion
Traditional measures of benefit in health-
care policies dictate the focus of interest for
research and the drug development process.
Although rare diseases are not considered a
public health priority, the sheer numbers of all
known rare tumors represent a significant bur-
den to society; for instance, it is believed that
more than 200 cancers with an incidence lower
than 40,000 cases are reported each year in the
United States, and they may account for up to
25% of the mortality by cancer in that coun-
try.
1,2 Despite efforts mainly driven by research
carried  out  in  developed  countries,  little
progress has been seen in the treatment of the
majority  of  rare  tumor  types.  Furthermore,
diagnosing rare tumors may be challenging,
and the scenario for the stricken individual is
further  darkened  by  the  lack  of  appropriate
knowledge about the course of disease and its
management. Not surprisingly, this outlook is
perceived as deeply frustrating by patients suf-
fering from such devastating disorders.
2
The reasons for this stagnation are multi-
factorial and could be discussed extensively.
One of the main problems is logistical as the
low incidence of the rare tumors makes the
patient  recruitment  process  cumbersome.
Therefore, a large number of institutions have
to become involved in even relatively small tri-
als,  making  them  complex,  slow,  and  costly;
one  obvious  consequence  is  a  high  rate  of
early trial termination owing to poor recruit-
ment,
3which accounts in part for the paucity of
evidence-based  data.  This  poor  accrual  is
caused not only by the small number of cases
but also by the unavailability of effective popu-
lation  screening  programs  and  education-
based  actions  (“disease  awareness”),  which
makes  early  diagnosis  elusive.  Moreover,
recruitment to clinical trials is further under-
mined  by  the  regrettable  tendency  to  keep
these patients in community hospitals instead
of referring them for treatment in highly spe-
cialized  institutions.  Fortunately,  important
initiatives are underway now, such as the ex  -
istence of international specialized scientific
journals  and  websites,  national  and  inter  -
national registries, and mounting pressure to
concentrate the treatment of uncommon cases
in highly specialized clinics. 
Our  current  model  of  drug  development,
which is highly business- and profit-oriented,
is also a handicap for those rare diseases with
regard  to  improvements  in  treatment.
Historically,  there  has  been  limited  interest
from pharmaceutical companies in investing
in innovation in diseases that will not make
their compounds a “best seller.” The restricted
market makes the intervention uninteresting
for patent-holders once the costs deriving from
development and regulatory approval process-
es are not likely to be recovered. Therefore, the
development of an “orphan drug” is particular-
ly challenging for a pharmaceutical company,
and  this  also  includes  the  development  of
accurate diagnostic methods. It is clear that
current pharmacoeconomic tools and market-
ing studies will not back investments in rare
diseases, and even promising compounds may
end up not being properly studied. However,
one has to admit that the current system has
undeniably led to remarkable progress in many
tumor types
4,5 and it is unlikely to be changed
in the near future. This indicates that alterna-
tive, creative strategies should be sought when
it comes to tackling the apparent stagnation in
the treatment of rare tumor types.
Notwithstanding, a less pessimistic outlook
has been proposed by renowned experts who
have postulated that “the physiologic basis for
tumors being rare is one and the same as the
reason that they are ultimately so treatable” or,
in other words, many of them could arise from
single  or  less  complex  genetic  aberrations.
6
This implies that the impact of the introduc-
tion of rationally developed compounds might
be higher in these cancer types
7 as compared
to more prevalent cancers such as breast, colo  -
rectal,  prostate,  and  lung  cancer,  which  are
driven by multiple genetic abnormalities that
could mitigate the biological effect of anti-can-
cer agents in a general patient population. 
Rare tumors are of public interest but not
necessarily a health priority, and thus specific
policies should be discussed. The Orphan Drug
Act  of  1983  from  the  United  States  and
EC141/2000 and 847/2000 from the European
Union  (EU)  legislation  came  into  force  in
order to create an incentive for the develop-
ment of treatments for rare diseases.
8-10 These
initiatives  have  been  recognized  as  major
steps  toward  promoting  equity  in  the  drug
development  process  for  diseases  with  dis-
parate prevalence. Since then, a growing num-
ber of orphan drugs have been registered; in
the 24 years since this law was passed in the
United States, 282 such drugs and biological
products, providing treatment for more than 14
million  patients  in  the  United  States,  have
come to market under its aegis. In the 8-10
years before 1982, in contrast, only 10 treat-
ments for rare diseases had been approved by
the FDA and brought to market.
11 However, at
least outside the United States, their accessi-
bility remains a concern.
12 For instance, in a
survey  commissioned  by  the  European
Commission and reported in 2004, only 9 of 25
EU member states had access to all 10 orphan
drugs approved in previous years and only one
member had all of them on the national reim-
bursement list.
13 The scenario appears to be
even  more  problematic  in  developing  coun-
tries. As per drugs approved in 2006-2007, the
EU orphan drugs included Atriance for acute
lymphoblastic  leukemia;  Evoltra  for  acute 
lymphoblastic leukemia; Nexavar for renal cell
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carcinoma;  Revlimid  for  multiple  myeloma;
Sprycel  for  chronic  myeloid  leukemia;  and
Sutent for gastrointestinal stromal tumors and
renal cell carcinoma.
12 As of May 2010, none of
them  was  widely  covered  by  the  National
Health System in emerging countries such as
Brazil, and this is probably the case in many
other developing nations.
Cancer  incidence  is  booming  in  emerging
countries,  and  the  national  rates  are  rapidly
reaching those reported in Western Europe and
North  America.
14 Clinical  research  has  also
boomed in developing countries over the last 10-
15 years,
15 and there is little evidence that this
tendency will be reverted over the next few years
or decades. Most of this progress is a result of
heavy  investment  and  commitment  from 
pharmaceutical companies. The sustainability of
clinical research in developing countries, how-
ever, remains highly dependent on pharmaceuti-
cal companies, and one challenge for a greater
participation  in  clinical  trials  targeting  rare
tumors  is  the  financial  incentive  from  trials
doomed to have low recruitment. On the other
hand, soaring costs with slow recruitment end
up intimidating pharmaceutical companies, in a
vicious cycle that is difficult to break. 
It is our view that academia could help partial-
ly fill this gap. Generally speaking, there is a
clear tendency from investigators to invest avail-
able public resources in tumors that have a high
incidence, which is understandable but redun-
dant, as these are the tumor types that already
benefit from a great deal of private investment.
Similarly, many unanswered questions are not
directly  related  to  drug  treatment  but  involve
more fundamental questions such as the role
and/or type of surgery, radiation therapy, appro-
priate tumor classification, or novel schedules
for currently available treatments instead of new
drugs.  These  questions  are  unlikely  to  be
addressed by trials sponsored by pharmaceutical
companies and could be preferentially addressed
by academic research in developing economies.
In  addition,  emerging  countries  should  take
advantage of a high incidence of some types of
cancer, some of them now considered rare in
developed countries, such as hepatocarcinoma
in parts of Asia, cholangiocarcinoma in Asia and
parts of South America, esophageal cancer in
Brazil,  gastric  cancer  in  South  America  and
parts of Asia, triple negative breast cancer in
Latin America, and cervical cancer in most of the
developing world. Comprehensive epidemiologi-
cal studies should be carried out in each emerg-
ing country, who should take the lead in the clin-
ical research process for those cancers. Finally,
basic research focusing on rare tumor types is
also likely to pay off in the long term as regards
academic  merit,  owing  to  lower  competition
when compared to the tumors with higher inci-
dence and issues related to the tumor biology
previously mentioned in this text.
6
Emerging  countries  should  also  consider
investing  in  organizational  infrastructure,
such  as  comprehensive,  accurate  national
databases  and  rare  tumor  registries.
Encouraging  the  development  of  reference
centers  focused  on  the  treatment  of  rare
tumors will pay off in the long term, and may
allow institutions to build expertise and boost
the  recruitment  of  these  patients  to  clinical 
trials, while providing the best possible med-
ical  care  to  patients.  The  establishment  of
effective regional, national, and international
research  collaboration  networks  (e.g.  Grupo
Latino  Americano  de  Investigações  Clínicas
em Oncologia - GLICO, Brazil) could also help
to boost accrual to trials in rare tumor types, as
effective  referral  networks  could  be  a  more
cost-effective strategy than opening trials in
multiple  sites  to  recruit  only  a  handful  of
patients.  The  lack  of  specific  legislation  for
research and development in rare diseases in
the  developing  world  is  also  a  problem  that
must be addressed; this includes taxing poli-
cies,  financial  incentives  (such  as  specific
grants  to  support  research),  marketing,  and
accessibility  to  approved  drugs.  This  would
also help to open pharmaceutical companies’
eyes  to  investing  in  rare  tumor  research  in
emerging countries either through national or
global initiatives.
In conclusion, the research process in rare
tumors has witnessed important initiatives but
is still relatively inefficient and needs improve-
ment urgently. This is particularly challenging
for  patients  and  investigators  in  emerging
countries who could do more to contribute to
this process. There are no easy solutions but a
number of aspects and potential solutions have
been raised by the authors in this article such
as: i) government participation in the develop-
ment of new agents in rare tumors; ii) incen-
tives in terms of extending patent life for devel-
opments reaching commercial level (similar to
what has been proposed in favor of develop-
ment of new agents against pediatric cancer);
iii) less stringent registration requirements for
active compounds, with greater acceptance of
non-randomized data as evidence of effective-
ness for rare diseases, with some successful
examples in the recent past;
7 iv) less bureau-
cracy in the clinical trials regulatory process
leading  to  lower  drug  development  costs;  v)
research  more  focused  on  specific,  relevant
molecular  processes  in  tumors,  leading  to
smaller clinical trials in enriched patient popu-
lations and faster drug development.
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